BR112014001299A2 - forma cristalina do sal de sódio de 4-terc-butil-n-[4-cloro-2-(1-óxi-piridina-4-carbonil)-fenil]-benzenossulfonamida - Google Patents

forma cristalina do sal de sódio de 4-terc-butil-n-[4-cloro-2-(1-óxi-piridina-4-carbonil)-fenil]-benzenossulfonamida

Info

Publication number
BR112014001299A2
BR112014001299A2 BR112014001299A BR112014001299A BR112014001299A2 BR 112014001299 A2 BR112014001299 A2 BR 112014001299A2 BR 112014001299 A BR112014001299 A BR 112014001299A BR 112014001299 A BR112014001299 A BR 112014001299A BR 112014001299 A2 BR112014001299 A2 BR 112014001299A2
Authority
BR
Brazil
Prior art keywords
carbonyl
chloro
tert
phenyl
butyl
Prior art date
Application number
BR112014001299A
Other languages
English (en)
Other versions
BR112014001299B1 (pt
Inventor
Andrew M K Pennell
Solomon Ungashe
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of BR112014001299A2 publication Critical patent/BR112014001299A2/pt
Publication of BR112014001299B1 publication Critical patent/BR112014001299B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

resumo patente de invenção: "forma cristalina do sal de sódio de 4-terc-butil-n-[4-cloro-2-(1-óxi-piridina-4-carbonil)-fenil]-benzenossulfonamida". a presente invenção refere-se a uma nova forma cristalina do sal de sódio da 4-terc-butil-n-[4-cloro-2-(1-óxi-piridina-4-carbonil)fenil]benzenossulfonamida e composições farmacêuticas que contenham a mesma. processos para a preparação das mesmas e métodos para o uso das mesmas também são descritos.
BR112014001299-7A 2011-07-22 2012-07-20 Forma cristalina anidra do sal sódico de 4-terc-butil-n-[4-cloro-2-(1-óxi-piridina-4-carbonil) -fenil]-benzenossulfonamida, composição farmacêutica, seus usos e método para a preparação de uma composição farmacêutica compreendendo a dita forma cristalina BR112014001299B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161510832P 2011-07-22 2011-07-22
US61/510,832 2011-07-22
PCT/US2012/047559 WO2013016174A1 (en) 2011-07-22 2012-07-20 A crystalline form of the sodium salt of 4-tert-butyl-n-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzene sulfonamide

Publications (2)

Publication Number Publication Date
BR112014001299A2 true BR112014001299A2 (pt) 2017-01-10
BR112014001299B1 BR112014001299B1 (pt) 2022-08-16

Family

ID=46599010

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014001299-7A BR112014001299B1 (pt) 2011-07-22 2012-07-20 Forma cristalina anidra do sal sódico de 4-terc-butil-n-[4-cloro-2-(1-óxi-piridina-4-carbonil) -fenil]-benzenossulfonamida, composição farmacêutica, seus usos e método para a preparação de uma composição farmacêutica compreendendo a dita forma cristalina

Country Status (20)

Country Link
US (1) US9133124B2 (pt)
EP (1) EP2748146B1 (pt)
JP (1) JP6122003B2 (pt)
CN (1) CN103842343B (pt)
AU (1) AU2012287160B2 (pt)
BR (1) BR112014001299B1 (pt)
CA (1) CA2841967C (pt)
DK (1) DK2748146T3 (pt)
ES (1) ES2625286T3 (pt)
HR (1) HRP20170745T1 (pt)
HU (1) HUE032747T2 (pt)
IL (1) IL230468B (pt)
MX (1) MX350269B (pt)
PL (1) PL2748146T3 (pt)
PT (1) PT2748146T (pt)
RS (1) RS56023B1 (pt)
RU (1) RU2607515C2 (pt)
SI (1) SI2748146T1 (pt)
WO (1) WO2013016174A1 (pt)
ZA (1) ZA201400474B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2842894A1 (en) * 2011-07-22 2013-01-31 Chemocentryx, Inc. Polymorphic forms of the sodium salt of 4-tert-butyl-n-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide
RU2607191C2 (ru) * 2011-07-22 2017-01-10 Хемоцентрикс, Инк. Полиморфные формы натриевой соли 4-трет-бутил-n-[4-хлор-2-(1-окси-пиридин-4-карбонил)-фенил]-бензолсульфонамида
EP3141235A1 (en) * 2012-12-06 2017-03-15 IP Gesellschaft für Management mbH N-(6-((2r,3s)-3,4-dihydroxybutan-2-yloxy)-2-(4-fluorobenzylthio)pyrimidin-4-yl)-3-methylazetidine-l -sulfonamide
US9822057B2 (en) 2013-03-14 2017-11-21 United Therapeutics Corporation Solid forms of treprostinil
JP6954834B2 (ja) 2014-10-06 2021-10-27 ケモセントリックス，インコーポレイティド ＣＣケモカイン受容体９（ＣＣＲ９）の阻害剤と抗α４β７インテグリン遮断抗体の併用療法
US10792360B1 (en) 2019-11-21 2020-10-06 Chemocentryx, Inc. Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies
TW202203916A (zh) 2020-03-31 2022-02-01 美商卡默森屈有限公司 使用ｃｃｒ９抑制劑及抗ｉｌ—２３阻斷抗體治療發炎性腸道疾病的組成物及方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826689A (en) 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
FR2634376B1 (fr) 1988-07-21 1992-04-17 Farmalyoc Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
IT1227626B (it) 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
IT1243390B (it) 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5552160A (en) 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
ATE150297T1 (de) 1992-06-10 1997-04-15 Nanosystems Llc Oberflaechenmodifizierte nsaid nanopartikeln
AU660852B2 (en) 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5346702A (en) 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5302401A (en) 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5340564A (en) 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en) 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5587143A (en) 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5585108A (en) 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5560932A (en) 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5569448A (en) 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5560931A (en) 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5571536A (en) 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5503723A (en) 1995-02-08 1996-04-02 Eastman Kodak Company Isolation of ultra small particles
US5518738A (en) 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5622938A (en) 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5591456A (en) 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5573783A (en) 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US5718919A (en) 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
US5565188A (en) 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US5747001A (en) 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
WO1998035666A1 (en) 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
MXPA04011465A (es) * 2002-05-24 2005-02-14 Millennium Pharm Inc Inhibidores de ccr9 y metodos de uso de los mismos.
DK1562940T3 (da) * 2002-11-18 2007-10-01 Chemocentryx Inc Arylsulfonamider
US20050250820A1 (en) * 2004-03-08 2005-11-10 Amgen Inc. Therapeutic modulation of PPARgamma activity
CA2566387A1 (en) * 2004-05-12 2005-12-01 Chemocentryx, Inc. Aryl sulfonamides as chemokine receptor ccr9 antagonists
ATE498615T1 (de) * 2006-07-14 2011-03-15 Chemocentryx Inc Triazolylphenylbenzensulfonamide
US20100234364A1 (en) * 2006-07-14 2010-09-16 Arindrajit Basak Ccr2 inhibitors and methods of use thereof
US8519135B2 (en) * 2006-07-14 2013-08-27 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2/CCR9
RU2607191C2 (ru) * 2011-07-22 2017-01-10 Хемоцентрикс, Инк. Полиморфные формы натриевой соли 4-трет-бутил-n-[4-хлор-2-(1-окси-пиридин-4-карбонил)-фенил]-бензолсульфонамида
CA2842894A1 (en) * 2011-07-22 2013-01-31 Chemocentryx, Inc. Polymorphic forms of the sodium salt of 4-tert-butyl-n-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide

Also Published As

Publication number Publication date
US20130059893A1 (en) 2013-03-07
IL230468B (en) 2018-05-31
DK2748146T3 (en) 2017-05-22
AU2012287160A1 (en) 2014-02-06
AU2012287160B2 (en) 2017-02-02
EP2748146A1 (en) 2014-07-02
HUE032747T2 (en) 2017-10-30
CA2841967C (en) 2020-06-16
MX2014000660A (es) 2014-07-09
CN103842343B (zh) 2016-08-31
BR112014001299B1 (pt) 2022-08-16
PL2748146T3 (pl) 2017-09-29
ES2625286T3 (es) 2017-07-19
MX350269B (es) 2017-08-31
RS56023B1 (sr) 2017-09-29
CA2841967A1 (en) 2013-01-31
US9133124B2 (en) 2015-09-15
ZA201400474B (en) 2015-03-25
SI2748146T1 (sl) 2017-10-30
WO2013016174A1 (en) 2013-01-31
JP6122003B2 (ja) 2017-04-26
JP2014524931A (ja) 2014-09-25
RU2014104993A (ru) 2015-11-20
PT2748146T (pt) 2017-05-29
IL230468A0 (en) 2014-03-31
CN103842343A (zh) 2014-06-04
HRP20170745T1 (hr) 2017-08-11
RU2607515C2 (ru) 2017-01-10
EP2748146B1 (en) 2017-03-08

Similar Documents

Publication Publication Date Title
BR112014001299A2 (pt) forma cristalina do sal de sódio de 4-terc-butil-n-[4-cloro-2-(1-óxi-piridina-4-carbonil)-fenil]-benzenossulfonamida
CO6640270A2 (es) Morfolinopirimidad y su uso en terapia
CY1118478T1 (el) Παραγωγα τυπου αζαϊνδαζολιου ή διαζαϊνδαζολιου για τη θεραπεια του πονου
PE20160874A1 (es) Compuestos quimicos
AR094204A1 (es) Composiciones para el cuidado oral que contienen haluros de acido amino
BR112014002946A2 (pt) sistema de travamento mecânico para painéis de piso
BRPI1006115A8 (pt) "agentes indutores de apoptose para o tratamento de câncer e doenças autoimunes".
UY32156A (es) Derivados sustituidos de la n2 - [1-(5 - fluoropirimidin -2-il) etil] - n4 - (1-metil - 1h-imidazol - 4 - il)) - pirimidina - 2,4 - diaminas y sus sales farmacéuticamente aceptables, proceso de preparación, composiciones conteniéndolos y aplicaciones.
BR112012021857A2 (pt) formas cristalinas para sal de sódio de 5-amino-2,3-di-hidro ftalazino-1,4-diona, preparações farmacêuticas contendo o mesmo e processo para a produção das ditas formas
BR112015014453A2 (pt) produtos de cuidado oral compreendendo cloreto de zinco tetrabásico e trimetilglicina
BR112012023660B8 (pt) usos de uma quantidade terapeuticamente eficaz de um composto, ou de um sal, solvato, hidrato ou pró-fármaco farmaceuticamente aceitável do mesmo para o tratamento de câncer
BR112014014452A2 (pt) derivados de pirazolpiridina, processo de preparação dos mesmos e uso terapêutico dos mesmos
BR112013011184A2 (pt) composições e métodos para tratamento de mielofibrose
BR112015004029A2 (pt) Processo para preparação de teneligliptina, de um composto ou de sal ou hidrato do mesmo
UY33191A (es) Derivados de pirazina
IL285667A (en) Polymorphic forms of the sodium salt of 4-tert-butyl-n-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzene sulfonamide
AR079050A1 (es) Compuestos benzoimidazolicos y sus usos
EA201600434A1 (ru) Применение производных бензимидазолпролина
EA201590041A1 (ru) Твердая форма холиновой соли вемурафениба
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды
EA201590250A1 (ru) Производные карбамат/мочевины
BR112017005218A2 (pt) mistura de compostos, processo para fabricar uma mistura, formulação aquosa, e, uso de misturas de compostos.
BR112014001530A2 (pt) formas polimórficas do sal de sódio de 4-terc-butil-n-[4-cloro-2-(1-óxi-piridina-4-carbonil)-fenil]-benzeno sulfonamida
CU20130001A7 (es) Forma cristalina delta de la sal de arginina de perindoprilo, su procedimiento de preparación, y las composiciones farmacéuticas que la contienen
BR112015006243A2 (pt) agentes antibacterianos de fenicol

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/07/2012, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.